Date: 2015-11-09
Type of information: Nomination
Compound:
Company: Bone Therapeutics (Belgium)
Therapeutic area: Bone diseases - Regenerative medicine
Type agreement: nomination
Action mechanism:
Disease:
Details: * On November 9, 2015, Bone Therapeutics announced the appointment of Thomas Lienard as Chief Business Officer with immediate effect. Mr Lienard (39) has over 15 years of national and international sales and marketing experience in the pharmaceutical industry. Prior to joining Bone Therapeutics, Mr Lienard worked at Lundbeck, where he acted as Managing Director for Belgium and Luxemburg and was vital to the launch of several products. He led a team of up to 80 employees, generating over € 50 million in sales. Before his position at Lundbeck, Mr Lienard worked at Eli Lilly and Company, where he held various positions in sales and marketing in Europe and the US, including Sales Director Belgium in 2010. Mr Lienard started his career in 1999 as consultant at McKinsey & Company. Mr Lienard graduated from Solvay Brussels School of Economics and Management as Master in Business Engineering in 1999 and obtained a Master of Business Administration (MBA) from Harvard Business School in Boston in 2004. At Bone Therapeutics, Mr Lienard will assume responsibility for activities regarding business development, business operations and strategic planning.
Financial terms:
Latest news:
